[BRNO Register 2: post-myocardial infarction pharmacotherapy]

J Spinar1, O Ludka, M Sepsi

  • 1Interní kardiologická klinika Lékarské fakulty MU a FN Brno. jspinar@fnbrno.cz

Vnitrni Lekarstvi
|August 5, 2010
PubMed

Insights

This study of 850 myocardial infarction patients found high guideline adherence for cardiovascular medications. However, optimal dosing of ACE inhibitors and statins was not consistently achieved, impacting patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacotherapy
  • Public Health

Context:

  • Assessed 850 patients with prior myocardial infarction (MI) history at Faculty Hospital Brno.
  • Cohort predominantly male (650 vs. 200) and under 70 years old (576 vs. 264).
  • Mean age at first MI: 59.0 years (men) vs. 65.5 years (women).

Purpose:

  • To evaluate pharmacotherapeutic adherence and clinical outcomes in post-myocardial infarction patients.
  • To identify potential gaps in guideline-directed medical therapy.
  • To analyze demographic and clinical characteristics influencing treatment.

Summary:

  • 75.8% received all guideline-recommended drug classes (RAAS blockers, beta-blockers, statins, antiplatelets).
  • Individual drug class use exceeded 90%, with no significant gender or age disparities.
  • Suboptimal dosing of ACE inhibitors and statins noted; Perindopril and Atorvastatin were most common.

Impact:

  • Identified high overall medication class prescription rates post-MI.
  • Highlighted need for optimizing medication dosages for improved cardiovascular risk management.
  • Provided insights into patient profiles and treatment patterns in a real-world clinical setting.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...